| |
KOMISJA NADZORU FINANSOWEGO |
|
| |
|
|
Raport bieżący nr |
12 |
/ |
2021 |
|
|
|
| |
Data sporządzenia: |
2021-05-17 |
|
|
|
|
|
|
|
|
|
| |
Skrócona nazwa emitenta |
|
|
|
|
|
|
|
|
|
| |
MILESTONE MEDICAL |
|
| |
Temat |
|
|
|
|
|
|
|
|
|
|
| |
The update on commercial rollout of CompuFlo Epidural System in the first quarter
2021
|
|
| |
Podstawa prawna |
|
|
|
|
|
|
|
|
| |
Art. 17 ust. 1 MAR - informacje poufne.
|
|
| |
Treść raportu: |
|
|
|
|
|
|
|
|
|
| |
The Board of Directors of Milestone Medical Inc. _WAR: MMD, “the Company", “the Issuer"_
today provided a business update for the first quarter ended March 31, 2021.
The Board of Directors of the Company informs that the Company’s primary focus has
been, and continues to be, the commercialization of the CompuFlo Epidural System.
Specifically, now that the Company has penetrated several medical institutions with
CompuFlo® Epidural Instrument and CathCheck™ System, the Issuer is aggressively building
its sales and marketing organization to prepare for the next phase of our growth.
The Board of Directors of the Company believes these latest commercial orders from
several recognized hospitals is validation that the technology provides a level of
safety and efficiency not currently available to medical professionals using conventional
syringes. The Board of Directors of the Company truly believes that 2021 will be a
transformative year for the medical business and an important turning point as Milestone
Scientific Inc., the parent of the Company _“MLSS"_ and the Company execute its joint
goal of establishing our medical instruments and disposables as the new standard of
care for epidural procedures in labor and delivery.
The strong balance sheet of MLSS with approximately $17 million of cash and cash equivalents
as of March 31, 2021, provides the Company with substantial resources and the ability
to accelerate the sales and marketing activities around both medical instruments.
It also allows MLSS and the Company to advance the development and commercialization
of other indications for our proprietary DPS Dynamic Pressure Sensing Technology,
which the Board of Directors of the Company believes represent further growth opportunities
for the Company. Additionally, last week the Company announced the appointment of
Arjan Haverhals as CEO of the Company and hired Scott Kahn as new CFO. Arjan has already
proven his exceptional leadership as President of MLSS, and Scott will be instrumental,
not only overseeing the financial infrastructure, but also helping to increase investor
awareness as the Company executes its key milestones. Leonard Osser is looking forward
to playing a counsel role in the further growth and success of the Company.
|
|
|
RB_ASO: The update on commercial rollout of CompuFlo Epidural System in the first quarter
2021
